Absence of an intrathecal immune reaction to a helper-dependent adenoviral vector delivered into the cerebrospinal fluid of non-human primates

被引:12
作者
Butti, E. [1 ]
Bergami, A. [1 ]
Recchia, A. [2 ,3 ]
Brambilla, E. [1 ]
Franciotta, D. [4 ]
Cattalini, A. [1 ]
Stornaiuolo, A. [5 ]
Lachapelle, F. [6 ]
Comi, G.
Mavilio, F.
Martino, G. [1 ]
Furlan, R. [1 ]
机构
[1] Ist Sci San Raffaele, Dept Neurol, Neuroimmunil Unit, I-20132 Milan, Italy
[2] Univ Modena, Dept Biomed Sci, I-41100 Modena, Italy
[3] Univ Reggio Emilia, Modena, Italy
[4] C Mondino Neurol Inst, Lab Neuroimmunol, Pavia, Italy
[5] Molmed SPA, Milan, Italy
[6] INSERM, UMR 546, BEA, Paris, France
关键词
helper-dependent adenoviral vectors; central nervous system; inflammation; immunogenicity;
D O I
10.1038/sj.gt.3303050
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Inflammation and immune reaction, or pre-existing immunity towards commonly used viral vectors for gene therapy severely impair long-term gene expression in the central nervous system (CNS), impeding the possibility to repeat the therapeutic intervention. Here, we show that injection of a helper-dependent adenoviral (HD-Ad) vector by lumbar puncture into the cerebrospinal fluid (CSF) of non-human primates allows long-term (three months) infection of neuroepithelial cells, also in monkeys bearing a pre-existing anti-adenoviral immunity. Intrathecal injection of the HD-Ad vector was not associated with any sign of systemic or local toxicity, nor by signs of a CNS-specific immune reaction towards the HD-Ad vector. Injection of HD-Ad vectors into the CSF circulation may thus represent a valuable approach for CNS gene therapy allowing for long-term expression and re-administration.
引用
收藏
页码:233 / 238
页数:6
相关论文
共 20 条
[1]   CEREBROSPINAL-FLUID IN THE DIAGNOSIS OF MULTIPLE-SCLEROSIS - A CONSENSUS REPORT [J].
ANDERSSON, M ;
ALVAREZCERMENO, J ;
BERNARDI, G ;
COGATO, I ;
FREDMAN, P ;
FREDERIKSEN, J ;
FREDRIKSON, S ;
GALLO, P ;
GRIMALDI, LM ;
GRONNING, M ;
KEIR, G ;
LAMERS, K ;
LINK, H ;
MAGALHAES, A ;
MASSARO, AR ;
OHMAN, S ;
REIBER, H ;
RONNBACK, L ;
SCHLUEP, M ;
SCHULLER, E ;
SINDIC, CJM ;
THOMPSON, EJ ;
TROJANO, M ;
WURSTER, U .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1994, 57 (08) :897-902
[2]  
CALLARD R, 1994, CYTOKINE FACTSBOOK, P53
[3]   Persistence in muscle of an adenoviral vector that lacks all viral genes [J].
Chen, HH ;
Mack, LM ;
Kelly, R ;
Ontell, M ;
Kochanek, S ;
Clemens, PR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) :1645-1650
[4]   Intrathecal gene delivery of glial cell line-derived neurotrophic factor ameliorated paraplegia in rats after spinal ischemia [J].
Chou, AK ;
Yang, LC ;
Wu, PC ;
Wong, WT ;
Liu, GS ;
Chen, JT ;
Howng, SL ;
Tai, MH .
MOLECULAR BRAIN RESEARCH, 2005, 133 (02) :198-207
[5]   Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity [J].
Driesse, MJ ;
Esandi, MC ;
Kros, JM ;
Avezaat, CJJ ;
Vecht, CJ ;
Zurcher, C ;
van der Velde, I ;
Valerio, D ;
Bout, A ;
Smitt, PAES .
GENE THERAPY, 2000, 7 (16) :1401-1409
[6]   Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice [J].
Furlan, R ;
Poliani, PL ;
Marconi, PC ;
Bergami, A ;
Ruffini, F ;
Adorini, L ;
Glorioso, JC ;
Comi, G ;
Martino, G .
GENE THERAPY, 2001, 8 (01) :13-19
[7]   An immunovirological study of central nervous system involvement during HIV-1 infection of chimpanzees [J].
Grimaldi, LME ;
Murthy, KK ;
Martino, G ;
Furlan, R ;
Franciotta, D ;
Eichberg, JW .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 13 (01) :12-17
[8]   Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial [J].
Kaplitt, Michael G. ;
Feigin, Andrew ;
Tang, Chengke ;
Fitzsimons, Helen L. ;
Mattis, Paul ;
Lawlor, Patricia A. ;
Bland, Ross J. ;
Young, Deborah ;
Strybing, Kristin ;
Eidelberg, David ;
During, Matthew J. .
LANCET, 2007, 369 (9579) :2097-2105
[9]   Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences [J].
Lowenstein, PR ;
Castro, MG .
GENE THERAPY, 2003, 10 (11) :946-954
[10]   The ependymal route to the CNS: an emerging gene-therapy approach for MS [J].
Martino, G ;
Furlan, R ;
Comi, G ;
Adorini, L .
TRENDS IN IMMUNOLOGY, 2001, 22 (09) :483-490